<p>Pathway Capital Management LP 在第三季度购买了 Hims &amp; Hers Health, Inc.（纽约证券交易所代码：HIMS - 免费报告）的新股份，根据该公司在最近向证券交易委员会（SEC）提交的 13F 文件。该机构投资者购买了 119,279 股公司股票，价值约为 6,766,000 美元。Hims &amp; Hers Health 占 Pathway Capital Management LP 持有股份的 33.3%，使其成为该公司最大的持仓。根据其最近向证券交易委员会（SEC）提交的文件，Pathway Capital Management LP 拥有 Hims &amp; Hers Health 的 0.05%。</p>
<p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<ul>
<li>在 2026 年第一季度之前购买的 5 只高空头头寸股票</li>
</ul>
<p>其他几家对冲基金最近也调整了对 HIMS 的持仓。维吉尼亚退休系统等在第三季度将其在 Hims &amp; Hers Health 的股份提高了 0.8%。维吉尼亚退休系统等现在拥有 25,600 股公司股票，价值 1,452,000 美元，此前在上个季度又购买了 200 股。GAMMA Investing LLC 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 6.1%。GAMMA Investing LLC 现在拥有 4,098 股公司股票，价值 232,000 美元，此前在此期间又购买了 236 股。Concurrent Investment Advisors LLC 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 1.8%。Concurrent Investment Advisors LLC 现在拥有 13,984 股公司股票，价值 793,000 美元，此前在此期间又购买了 252 股。Bessemer Group Inc. 在第二季度将其在 Hims &amp; Hers Health 的持仓增加了 105.8%。Bessemer Group Inc. 现在拥有 607 股公司股票，价值 30,000 美元，此前在上个季度又购买了 312 股。最后，True Vision MN LLC 在第二季度将其在 Hims &amp; Hers Health 的股份增加了 3.6%。True Vision MN LLC 现在拥有 9,376 股公司股票，价值 467,000 美元，此前在此期间又购买了 328 股。机构投资者和对冲基金持有公司股票的 63.52%。</p>
<h2>Hims &amp; Hers Health 价格表现</h2>
<p>Hims（纽约证券交易所代码：HIMS）周二开盘价为 26.45 美元。该公司的债务与股本比率为 1.67，速动比率为 1.64，流动比率为 1.88。该公司的市值为 60.2 亿美元，市盈率为 48.97，市盈增长比率为 4.46，贝塔值为 2.37。Hims &amp; Hers Health, Inc. 的一年低点为 23.97 美元，一年高点为 72.98 美元。该股票的 50 日移动平均线为 34.11 美元，200 日移动平均线为 44.09 美元。</p>
<ul>
<li>Hims、Block 和 NRG 刚刚启动了大规模股票回购</li>
</ul>
<p>Hims &amp; Hers Health（纽约证券交易所代码：HIMS - 获取免费报告）最近于 11 月 3 日发布了其财报。该公司报告本季度每股收益（EPS）为 0.06 美元，低于分析师一致预期的 0.09 美元，差额为 0.03 美元。该公司在本季度的收入为 5.9898 亿美元，而分析师预期为 5.7899 亿美元。Hims &amp; Hers Health 的净利润率为 6.05%，股本回报率为 24.67%。Hims &amp; Hers Health 本季度的收入同比增长 49.2%。在去年同期，该公司每股收益为 0.32 美元。整体来看，股票分析师预计 Hims &amp; Hers Health, Inc. 本财年将发布 0.29 美元的每股收益。</p>
<p>Hims &amp; Hers Health 宣布其董事会已于 11 月 17 日批准了一项股票回购计划，允许公司回购 2.5 亿美元的流通股。该回购授权允许公司通过公开市场购买最多 3% 的股票。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>MarketBeat 周报 – 11/17 - 11/21</li>
</ul>
<p>HIMS 最近成为几份分析师报告的主题。Wall Street Zen 在 11 月 8 日的研究报告中将 Hims &amp; Hers Health 的评级从 “持有” 下调至 “卖出”。Zacks Research 在 1 月 19 日的研究报告中将 Hims &amp; Hers Health 的评级从 “持有” 下调至 “强烈卖出”。美国银行在 11 月 4 日的研究报告中将 Hims &amp; Hers Health 的目标价从 28.00 美元上调至 32.00 美元，并给予该公司 “表现不佳” 的评级。Evercore ISI 在 1 月 12 日的报告中开始覆盖 Hims &amp; Hers Health 的股票。他们给予了 “持平” 的评级和 33.00 美元的目标价。最后，巴克莱在 12 月 8 日的报告中开始覆盖 Hims &amp; Hers Health 的股票。他们对该股票设定了 “增持” 评级和 48.00 美元的目标价。一位投资分析师对该股票给予了强烈买入评级，三位给予了买入评级，九位给予了持有评级，四位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 42.62 美元。</p>
<p><strong>查看我们关于 HIMS 的最新报告</strong></p>
<h2>Hims &amp; Hers Health 的内部活动</h2>
<p>在 Hims &amp; Hers Health 的其他新闻中，内部人士 Deborah M. Autor 于 12 月 17 日星期三出售了 7,054 股公司股票。股票的平均售价为 36.71 美元，总价值为 258,952.34 美元。交易后，该内部人士持有 6,175 股公司股票，估值约为 226,684.25 美元。这代表其持股减少了 53.32%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。此外，首席运营官 Michael Chi 于 12 月 17 日星期三出售了 13,750 股 Hims &amp; Hers Health 股票。股票的平均售价为 36.71 美元，总交易额为 504,762.50 美元。出售后，首席运营官直接持有 305,161 股公司股票，估值为 11,202,460.31 美元。这笔交易代表其持股减少了 4.31%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去一个季度中，内部人士已出售 131,974 股公司股票，价值 4,763,800 美元。公司内部人士持有公司股票的 13.71%。</p>
<h2>Hims &amp; Hers Health 概况</h2>
<p>(免费报告)</p>
<p>Hims &amp; Hers Health, Inc 是一个远程医疗平台，提供直接面向消费者的个人护理产品和虚拟医疗服务，服务于美国市场。该公司以 Hims &amp; Hers 品牌运营，提供一个综合数字体验，将用户与持牌医疗提供者连接，使其能够进行在线咨询和开处方，涵盖多种健康问题。其远程医疗基础设施支持处方药和非处方产品，并提供送货上门服务。</p>
<p>公司的产品组合涵盖男性和女性健康的关键领域，包括脱发治疗、性健康疗法、护肤方案和心理健康支持。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Hims &amp; Hers Health</li>
<li>黄金市场崩溃的那一天</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>~15,000 亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>黄金正在变得稀缺。</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
</ul>
<p><strong>想看看其他对 HIMS 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Hims &amp; Hers Health, Inc. (NYSE:HIMS - 免费报告) 的最新 13F 备案和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普医疗保健服务 ETF - SPDR

医疗业 ETF - SPDR

2 倍做多 HIMS ETF - Defiance

医疗业 ETF - Vanguard

美国医疗保健供应商 ETF - iShares

HIMS

HIMY

标普全球医疗股指数 ETF - iShares

<p>Pathway Capital Management LP 收购了 119,279 股 Hims & Hers Health, Inc.（NYSE:HIMS），价值约为 677 万美元，使其成为其投资组合中最大的持仓。其他机构投资者也增加了对 Hims & Hers Health 的持股。该公司报告了上个季度的收入为 5.9898 亿美元，未能达到每股收益预期，但显示出同比 49.2% 的收入增长。Hims & Hers Health 的董事会批准了一项 2.5 亿美元的股票回购计划，表明对股票价值的信心</p>

<p>Pathway Capital Management LP bought a new position in shares of Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 119,279 shares of the company's stock, valued at approximately $6,766,000. Hims &amp; Hers Health accounts for 33.3% of Pathway Capital Management LP's holdings, making the stock its largest position. Pathway Capital Management LP owned 0.05% of Hims &amp; Hers Health as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Pathway Capital Management LP 在第三季度购买了 Hims &amp; Hers Health, Inc.（纽约证券交易所代码：HIMS - 免费报告）的新股份，根据该公司在最近向证券交易委员会（SEC）提交的 13F 文件。该机构投资者购买了 119,279 股公司股票，价值约为 6,766,000 美元。Hims &amp; Hers Health 占 Pathway Capital Management LP 持有股份的 33.3%，使其成为该公司最大的持仓。根据其最近向证券交易委员会（SEC）提交的文件，Pathway Capital Management LP 拥有 Hims &amp; Hers Health 的 0.05%。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><ul>
<li>5 High Short-Interest Stocks to Buy Before Q1 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>在 2026 年第一季度之前购买的 5 只高空头头寸股票</li>
</ul>
</div><p>Several other hedge funds have also recently modified their holdings of HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Hims &amp; Hers Health by 0.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company's stock valued at $1,452,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Hims &amp; Hers Health by 6.1% in the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company's stock valued at $232,000 after purchasing an additional 236 shares during the period. Concurrent Investment Advisors LLC grew its holdings in shares of Hims &amp; Hers Health by 1.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company's stock worth $793,000 after purchasing an additional 252 shares during the period. Bessemer Group Inc. increased its holdings in Hims &amp; Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Finally, True Vision MN LLC increased its stake in Hims &amp; Hers Health by 3.6% during the second quarter. True Vision MN LLC now owns 9,376 shares of the company's stock worth $467,000 after purchasing an additional 328 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也调整了对 HIMS 的持仓。维吉尼亚退休系统等在第三季度将其在 Hims &amp; Hers Health 的股份提高了 0.8%。维吉尼亚退休系统等现在拥有 25,600 股公司股票，价值 1,452,000 美元，此前在上个季度又购买了 200 股。GAMMA Investing LLC 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 6.1%。GAMMA Investing LLC 现在拥有 4,098 股公司股票，价值 232,000 美元，此前在此期间又购买了 236 股。Concurrent Investment Advisors LLC 在第三季度将其在 Hims &amp; Hers Health 的持仓增加了 1.8%。Concurrent Investment Advisors LLC 现在拥有 13,984 股公司股票，价值 793,000 美元，此前在此期间又购买了 252 股。Bessemer Group Inc. 在第二季度将其在 Hims &amp; Hers Health 的持仓增加了 105.8%。Bessemer Group Inc. 现在拥有 607 股公司股票，价值 30,000 美元，此前在上个季度又购买了 312 股。最后，True Vision MN LLC 在第二季度将其在 Hims &amp; Hers Health 的股份增加了 3.6%。True Vision MN LLC 现在拥有 9,376 股公司股票，价值 467,000 美元，此前在此期间又购买了 328 股。机构投资者和对冲基金持有公司股票的 63.52%。</p>
</div><h2>Hims &amp; Hers Health Price Performance</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 价格表现</h2>
</div><p>Shares of NYSE:HIMS opened at $26.45 on Tuesday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The company has a market capitalization of $6.02 billion, a PE ratio of 48.97, a price-to-earnings-growth ratio of 4.46 and a beta of 2.37. Hims &amp; Hers Health, Inc. has a one year low of $23.97 and a one year high of $72.98. The stock has a fifty day moving average of $34.11 and a 200-day moving average of $44.09.</p>
<div class="lb-trans"><p>Hims（纽约证券交易所代码：HIMS）周二开盘价为 26.45 美元。该公司的债务与股本比率为 1.67，速动比率为 1.64，流动比率为 1.88。该公司的市值为 60.2 亿美元，市盈率为 48.97，市盈增长比率为 4.46，贝塔值为 2.37。Hims &amp; Hers Health, Inc. 的一年低点为 23.97 美元，一年高点为 72.98 美元。该股票的 50 日移动平均线为 34.11 美元，200 日移动平均线为 44.09 美元。</p>
</div><ul>
<li>Hims, Block, and NRG Just Launched Huge Stock Buybacks</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims、Block 和 NRG 刚刚启动了大规模股票回购</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.03). The business had revenue of $598.98 million during the quarter, compared to analysts' expectations of $578.99 million. Hims &amp; Hers Health had a net margin of 6.05% and a return on equity of 24.67%. Hims &amp; Hers Health's revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.32 EPS. As a group, equities analysts anticipate that Hims &amp; Hers Health, Inc. will post 0.29 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health（纽约证券交易所代码：HIMS - 获取免费报告）最近于 11 月 3 日发布了其财报。该公司报告本季度每股收益（EPS）为 0.06 美元，低于分析师一致预期的 0.09 美元，差额为 0.03 美元。该公司在本季度的收入为 5.9898 亿美元，而分析师预期为 5.7899 亿美元。Hims &amp; Hers Health 的净利润率为 6.05%，股本回报率为 24.67%。Hims &amp; Hers Health 本季度的收入同比增长 49.2%。在去年同期，该公司每股收益为 0.32 美元。整体来看，股票分析师预计 Hims &amp; Hers Health, Inc. 本财年将发布 0.29 美元的每股收益。</p>
</div><p>Hims &amp; Hers Health declared that its board has approved a share repurchase program on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health 宣布其董事会已于 11 月 17 日批准了一项股票回购计划，允许公司回购 2.5 亿美元的流通股。该回购授权允许公司通过公开市场购买最多 3% 的股票。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>MarketBeat Week in Review – 11/17 - 11/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 11/17 - 11/21</li>
</ul>
</div><p>HIMS has been the subject of several recent analyst reports. Wall Street Zen cut Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Zacks Research downgraded shares of Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Monday, January 19th. Bank of America increased their price objective on Hims &amp; Hers Health from $28.00 to $32.00 and gave the company an &#34;underperform&#34; rating in a research note on Tuesday, November 4th. Evercore ISI started coverage on shares of Hims &amp; Hers Health in a report on Monday, January 12th. They issued an &#34;in-line&#34; rating and a $33.00 target price for the company. Finally, Barclays initiated coverage on shares of Hims &amp; Hers Health in a report on Monday, December 8th. They set an &#34;overweight&#34; rating and a $48.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $42.62.</p>
<div class="lb-trans"><p>HIMS 最近成为几份分析师报告的主题。Wall Street Zen 在 11 月 8 日的研究报告中将 Hims &amp; Hers Health 的评级从 “持有” 下调至 “卖出”。Zacks Research 在 1 月 19 日的研究报告中将 Hims &amp; Hers Health 的评级从 “持有” 下调至 “强烈卖出”。美国银行在 11 月 4 日的研究报告中将 Hims &amp; Hers Health 的目标价从 28.00 美元上调至 32.00 美元，并给予该公司 “表现不佳” 的评级。Evercore ISI 在 1 月 12 日的报告中开始覆盖 Hims &amp; Hers Health 的股票。他们给予了 “持平” 的评级和 33.00 美元的目标价。最后，巴克莱在 12 月 8 日的报告中开始覆盖 Hims &amp; Hers Health 的股票。他们对该股票设定了 “增持” 评级和 48.00 美元的目标价。一位投资分析师对该股票给予了强烈买入评级，三位给予了买入评级，九位给予了持有评级，四位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标价为 42.62 美元。</p>
</div><p><strong>View Our Latest Report on HIMS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 HIMS 的最新报告</strong></p>
</div><h2>Insider Activity at Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 的内部活动</h2>
</div><p>In other Hims &amp; Hers Health news, insider Deborah M. Autor sold 7,054 shares of the company's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the transaction, the insider owned 6,175 shares in the company, valued at approximately $226,684.25. This represents a 53.32% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, COO Michael Chi sold 13,750 shares of Hims &amp; Hers Health stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer directly owned 305,161 shares of the company's stock, valued at $11,202,460.31. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 131,974 shares of company stock worth $4,763,800. Company insiders own 13.71% of the company's stock.</p>
<div class="lb-trans"><p>在 Hims &amp; Hers Health 的其他新闻中，内部人士 Deborah M. Autor 于 12 月 17 日星期三出售了 7,054 股公司股票。股票的平均售价为 36.71 美元，总价值为 258,952.34 美元。交易后，该内部人士持有 6,175 股公司股票，估值约为 226,684.25 美元。这代表其持股减少了 53.32%。该交易已在证券交易委员会的备案中披露，相关信息可通过 SEC 网站获取。此外，首席运营官 Michael Chi 于 12 月 17 日星期三出售了 13,750 股 Hims &amp; Hers Health 股票。股票的平均售价为 36.71 美元，总交易额为 504,762.50 美元。出售后，首席运营官直接持有 305,161 股公司股票，估值为 11,202,460.31 美元。这笔交易代表其持股减少了 4.31%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去一个季度中，内部人士已出售 131,974 股公司股票，价值 4,763,800 美元。公司内部人士持有公司股票的 13.71%。</p>
</div><h2>Hims &amp; Hers Health Profile</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 概况</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims &amp; Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc 是一个远程医疗平台，提供直接面向消费者的个人护理产品和虚拟医疗服务，服务于美国市场。该公司以 Hims &amp; Hers 品牌运营，提供一个综合数字体验，将用户与持牌医疗提供者连接，使其能够进行在线咨询和开处方，涵盖多种健康问题。其远程医疗基础设施支持处方药和非处方产品，并提供送货上门服务。</p>
</div><p>The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.</p>
<div class="lb-trans"><p>公司的产品组合涵盖男性和女性健康的关键领域，包括脱发治疗、性健康疗法、护肤方案和心理健康支持。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>The day the gold market broke</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>Gold’s getting scarce.</li>
<li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Hims &amp; Hers Health</li>
<li>黄金市场崩溃的那一天</li>
<li>忘掉人工智能，这将是下一个重大科技突破</li>
<li>~15,000 亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>黄金正在变得稀缺。</li>
<li>警报：在明天市场开盘前抛售这五只股票！</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding HIMS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 HIMS 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Hims &amp; Hers Health, Inc. (NYSE:HIMS - 免费报告) 的最新 13F 备案和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

119,279 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Pathway Capital Management LP

Market Beat

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Pathway Capital Management LP 购入了 119,279 股 Hims & Hers Health, Inc.的股票，股票代码为$HIMS